In this issue:
Mechanistic basis of durable disease control in metastatic urothelial cancer
HER2-positivity & ADCs in urothelial cancer
Olaparib in metastatic urothelial cancer with DNA damage response gene alterations
CFI & 1-year mortality following radical cystectomy
Adherence to QCIs for TURBT in NMIBC
Neoadjuvant aMVAC in older patients with MIBC
No changes in readmission after radical cystectomy in era of ERAS
Efficacy & timing of adjuvant chemotherapy in UTUC
Real-world first-line treatments & OS in locally advanced/metastatic urothelial carcinoma
Hypofractionated radiation therapy for bladder cancer
Please login below to download this issue (PDF)